ADVENT Post Approval Study

Inclusion Criteria:

• Subjects with drug-refractory, recurrent, symptomatic paroxysmal atrial fibrillation (PAF) who are indicated for a treatment with the FARAPULSE Pulsed Field Ablation (PFA) System*; (Subjects refractory, or intolerant or contraindicated to at leastone class I or III antiarrhythmic medication or contraindicated to any class I orIII medications.)

• Subjects who are willing and capable of providing informed consent;

• Subjects who are willing and capable of participating in all testing and follow-upassociated with this clinical study at an approved clinical investigational site;

• Subjects who are of legal age to give informed consent specific to the national law.

• For the LUX-Dx Sub-Study: Subjects with an existing LUX-Dx Insertable CardiacMonitor (ICM), inserted ≥ 180 days prior to enrollment, or having a LUX-Dx ICMinserted per the investigator's standard of care, up to 7 days after the ablationprocedure. Subjects with or having a LUX-Dx ICM inserted per standard of care, up to 7 days after the ablation procedure.

Exclusion Criteria:

• Subjects with any known contraindication to an AF ablation or anticoagulation,including those listed in the Instructions For Use (IFU);

• Subjects with any prior left atrium (LA) ablation;

• Subjects who may need an ablation in the left atrium besides PVI, such as forleft-sided atrioventricular reentrant tachycardia (AVRT), left-sided atrialtachycardia (AT) or atypical left-sided atrial flutter (AFL);

• Women of childbearing potential who are or plan to become pregnant during the timeof the study (assessment per investigator's discretion);

• Life expectancy of < 1 year, per investigator's medical judgement.